MiRNA-142-3p increases radiosensitivity in human umbilical cord blood mononuclear cells by inhibiting the expression of CD133

Fang Yuan¹, Lu Liu², Yonghong Lei³ & Yi Hu¹

This study is to explore the molecular regulation mechanism of CD133 which is associated with malignancy and poor prognosis of blood system diseases. CD133⁺ HUCB-MNC (human umbilical cord blood mononuclear cells) and CD133⁻ HUCB-MNC were isolated and amplified from umbilical cord blood, and then were exposed to different doses of radiation and subjected to a clonogenic assay. CCK-8 kit was used to detect cell viability, Annexin V-FITC/PI cell apoptosis detection kit was used for the detection of apoptotic cells and the BrdU assay was performed by flow cytometry. The expression of protein was analyzed by western blots. The profile of miRNA expression in response to radiation was examined and validated by RT-PCR. miR-142-3p inhibited the expression of CD133 in umbilical cord blood mononuclear cells to increase radiosensitivity. CD133⁺ HUCB-MNC cells were more radioresistant compared with CD133⁻ HUCB-MNC cells. CD133⁺ HUCB-MNC cells showed higher p-AKT and p-ERK levels after radiation. And miR-142-3p acted on 3'UTR of CD133 mRNA to inhibit CD133 expression. Moreover, miRNA-142-3p mimic increased radiosensitivity in CD133⁺ HUCB-MNC cells. Our results elucidated a novel regulation pathway in hematopoietic stem cells and suggested a potential therapeutic approach for blood system diseases therapy.

Radiotherapy is widely used for cancer treatment and the most common side effect is the bone marrow suppression¹. Human umbilical cord blood mononuclear cells (hUCB-MNCs) is a suitable source of progenitor and stem cells, including subcomponents such as hematopoietic stem cells (HSCs), mesenchymal stem cell (MSCs), and endothelial progenitor cells (EPCs). Umbilical cord blood stem cells possess multi-differentiation potentials as mesoblast precursor² which can differentiate into leukocytes, adipocytes, osteoblasts, muscle tendons and cardiocytes under the proper induction conditions³. Umbilical cord blood stem cells can differentiate into endothelial cells or MSCs both in vitro and in vivo and improve the poorly functioning organs⁴. Intracranial injection of hUCB-MNC during the hyperacute phase of ischemic stroke could improve cerebrovascular function and reduce infarct volume and behavioral deficits⁵.

The CD133 is a transmembrane glycoprotein which is considered as a significant cancer-associated cell surface marker. The expression of CD133 has been elevated in plenty of cancer cell types. CD133⁺ colon cancer cells showed chemo-resistance to 5-fluorouracil by increasing the survivin expression⁶. CD133 facilitates the CSC-like properties by stabilizing EGFR-AKT signaling in Hepatocellular carcinoma cells (HCC)⁷. CD133 is a positive marker for a specific class of human cord blood-derived CD34-negative HSCs⁸. Radiotherapy leads to myelosuppression, while CD133 could resist radiotherapy-induced bone marrow suppression⁹. CD133⁺ cells were the source of most of the stem cells present in the HUCB-MNC, and CD133 was critical for the radiosensitivity of HUCB-MNCs¹⁰.

MicroRNAs (miRNAs) are key regulators for some cellular processes. Specific expression signatures have been found in different blood cell lineages and stages of HSC differentiation during hematopoiesis¹¹. MiRNAs are small, non-coding RNAs found in the eukaryotes that control the expression of a large number of genes¹² involved in commitment and differentiation of hematopoietic stem cells and tumorigenesis¹³. In particular, there

¹ Department of Oncology, Chinese PLA General Hospital, Beijing, 100853, China. ² Department of Clinical Nutrition, Chinese PLA General Hospital, Beijing, 100853, China. ³ Department of Plastic Surgery, Chinese PLA General Hospital, Beijing, 100853, China. Fang Yuan and Lu Liu contributed equally to this work. Correspondence and requests for materials should be addressed to Y.L. (email: lyhlx@126.com) or Y.H. (email: huyi0401@aliyun.com)
has been a growing body of evidence supporting the role of miRNA in the regulation of CSCs recently. For example, microRNA-139-5p regulates the proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.

Therefore, alterations in miRNAs can contribute to the inhibition of HSCs differentiation. MicroRNA-134-3p is a new potential inhibitor of human ovarian CSCs by targeting the RARβ2A. We-Wei Shen et al. reported that miR-142-3p functioned as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. In this study, we identified miR-142-3p as a key modulator of CD133+ HUCB-MNC cells through pathways involving CD133, AKT and ERK pathways.

**Results**

**In vitro isolation and amplification of CD133+ HUCB-MNC and CD133− HUCB-MNC.** An appropriate source of HSCs is in the mononuclear cell (MNC) fraction of human umbilical cord blood (HUCB). HUCB-MNC cells were isolated from umbilical cord blood, and the surface markers of these cells were analyzed by flow cytometry assay, including CD29 (51.02% ± 7.95%), CD44 (64.33% ± 7.45%), CD90 (57.63% ± 10.99%), CD34 (48.93% ± 5.32%), CD45 (2.67% ± 1.71%), CD117 (5.33% ± 1.69%) and CD133 (8.63% ± 0.67%) as shown in Fig. 1A–G and summarized in Fig. 1H. Furthermore, a stem cell enriched fraction (CD133+/HUCB-MNC, 91.5% CD133-positive cells) and a stem cell depleted fraction (CD133− HUCB-MNC, 1.37% CD133-positive cells) of HUCB-MNC were sorted by flow cytometry (Fig. 1I–K). Cell culture images of FACS-sorted CD133+ and CD133− HUCB-MNC cells were shown in Fig. 1L.

**CD133+ HUCB-MNC cells were more radioresistant compared with CD133− HUCB-MNC cells.** To explore the effect of CD133 on the cell response to radiation, CD133+ HUCB-MNC cells and CD133− HUCB-MNC cells were exposed to different doses of radiation and subjected to a clonogenic assay. Cell colonies were counted and radiobiological parameters were calculated by survival curves for each cell type. Compared with the CD133− HUCB-MNC cells in the control group, the survival fractions of CD133+/HUCB-MNC cells were much higher at 4 Gy (0.361 ± 0.057 vs 0.198 ± 0.034, p < 0.01), 6 Gy (0.158 ± 0.039 vs 0.071 ± 0.028, p < 0.001) and 8 Gy (0.065 ± 0.027 vs 0.008 ± 0.005, p < 0.001) radiation dose (Fig. 2A). Representative photomicrographs of cell colonies formed by CD133+/− HUCB-MNC cells at 8 Gy radiation dose were shown in Fig. 2B. The CCK8 proliferation assay results showed that the growth rate of CD133− cells was significantly decreased after radiation, compared with that of the CD133+ cells at 4 Gy (0.356 ± 0.040 vs 0.507 ± 0.023, p < 0.05), 6 Gy (0.221 ± 0.025 vs 0.347 ± 0.057, p < 0.01) and 8 Gy (0.110 ± 0.016 vs 0.238 ± 0.043, p < 0.01) radiation dose (Fig. 2C). We further looked into the effects of CD133 on the cell apoptosis after graded doses (0, 2, 4, 6, 8 Gy) radiation (Fig. 2D). As shown in Fig. 2D, the proportion of apoptosis decreased in the CD133+/− HUCB-MNC cells compared with CD133− HUCB-MNC cells at 2 Gy (10.53% ± 1.40% vs 18.12% ± 2.36%, p < 0.05), 4 Gy (22.03% ± 2.93% vs 36.36% ± 3.76%, p < 0.01), 6 Gy (31.96% ± 3.82% vs 52.87% ± 5.03%, p < 0.01) and 8 Gy (41.30% ± 3.58% vs 60.91% ± 3.98%, p < 0.01) radiation dose. Cell cycle is one of the crucial factors that affects radioresistance. To examine the CD133-mediated effect on the cell cycle, flow cytometry was performed to analyze the effect of CD133 on the cell cycle (Fig. 2E,G). The proportion of S phase cells increased in the CD133+/− HUCB-MNC cells compared with CD133− HUCB-MNC cells at 6 Gy (12.80% ± 1.41% vs 9.61% ± 1.49%, p < 0.05) and 8 Gy (10.23% ± 1.01% vs 8.39% ± 0.95%, p < 0.05) radiation doses. These results indicated that CD133+/− HUCB-MNC cells were more radioresistant compared with CD133− HUCB-MNC cells due to an increase in the proliferation rate, a decrease in the radiation induced apoptosis and prolonged S phase after radiation exposure.

**CD133+ HUCB-MNC cells showed higher p-AKT and p-ERK levels after radiation.** Signaling through the AKT and ERK pathways controls the cell proliferation. Western blots were used to analyze p-AKT, t-AKT, p-ERK (T202/Y204), t-ERK expression (Fig. 3A). The proportion of p-AKT/ t-AKT increased in the CD133+/− HUCB-MNC cells compared with CD133− HUCB-MNC cells at 6 Gy (0.442 ± 0.087 vs 0.150 ± 0.016, p < 0.01) and 8 Gy (0.207 ± 0.040 vs 0.103 ± 0.031, p < 0.05) radiation dose (Fig. 3B). The proportion of p-ERK (T202/Y204)/t-ERK increased in the CD133+/− HUCB-MNC cells compared with CD133− HUCB-MNC cells at 4 Gy (0.437 ± 0.076 vs 0.333 ± 0.071, p < 0.05), 6 Gy (0.220 ± 0.050 vs 0.170 ± 0.079, p < 0.05) and 8 Gy (0.143 ± 0.035 vs 0.100 ± 0.026, p < 0.05) radiation dose (Fig. 3C). However, no effect was observed on AKT and ERK mRNA levels (Fig. 3D,E). These results indicated that CD133+/− HUCB-MNC cells showed higher p-AKT and p-ERK levels after radiation.

**Screening of miRNAs Regulating CD133 Expression and miRNA validation by RT-PCR.** Combined with CD133 molecular regulation and human umbilical cord blood mononuclear cells expressed miRNA two aspects of information, the final confirmation of the following 12 miRNA: hsa-miR-29a-3p (Fig. 4A), hsa-miR-29b-3p (Fig. 4B), hsa-miR-200c-3p (Fig. 4C), hsa-miR-4423-5p (Fig. 4D), hsa-miR-335-3p (Fig. 4E), hsa-miR-142-5p (Fig. 4G), hsa-miR-22-3p (Fig. 4H), hsa-miR-30a-3p (Fig. 4I), hsa-miR-30e-5p (Fig. 4J), hsa-miR-377-3p (Fig. 4K) and hsa-miR-4739 (Fig. 4L) showed no difference between CD133+/− HUCB-MNC cells and CD133− HUCB-MNC cells. Mir-142-3p levels were reduced in CD133+ positive cells compared to cells that were CD133 negative (0.567 ± 0.032 vs 1.030 ± 0.125, p < 0.01), 6 Gy radiation decreased mir-142-3p expression both in CD133 positive and CD133 negative cells (0.180 ± 0.087 vs 0.547 ± 0.067, p < 0.01) (Fig. 4F).

**Mir-142-3p acted on 3′UTR of CD133 mRNA to inhibit CD133 expression.** The results of a luciferase assay showed that mir-142-3p silenced CD133 by binding to the 3′-UTR of CD133 mRNA. Mir-142-3p mimic significantly reduced CD133 mRNA levels compared with the mimic control (10 nM, 73.78% ± 8.724% vs 102.567% ± 11.073%, p < 0.01; 20 nM, 37.467% ± 5.054% vs 102.567% ± 11.073%, p < 0.001; 50 nM, 27.200% ± 6.873% vs 102.567% ± 11.073%, p < 0.001), and there was no difference between the mimic control group and the pmirGLO vector group (102.567% ± 11.073% vs 102.033% ± 3.099%, p > 0.05) (Fig. 5A). Transfection of
miR-142-3p mimics in CD133+HUCB-MNC cells downregulated CD133 expression compared with the mimic control both in mRNA (10 nM, 0.672 ± 0.136 vs 0.979 ± 0.152, p < 0.01; 20 nM, 0.233 ± 0.082 vs 0.979 ± 0.152, p < 0.001; 50 nM, 0.155 ± 0.059 vs 0.979 ± 0.152, p < 0.001) and protein levels (Fig. 5B,D). And transfection of

Figure 1. *In vitro* isolation and amplification of CD133+HUCB-MNC and CD133−HUCB-MNC. (A–H) Represent detection results of CD29, CD44, CD34, CD90, CD45, CD117 and CD133 in HUCB-MNC cells. (I) represents cells before sorting. (J) Meant after sorting of CD133− cells. (K) represents cells after sorting of CD133+HUCB-MNC. (L) FACS-sorted CD133− cells (left) and CD133+ cells (right) were cultured in Iscove’s modified Dulbecco’s medium containing growth factors and cytokines. Scale bar = 50 μm. Assays were repeated three times. *P < 0.05, compared with the control group.
miR-142-3p inhibitors in CD133+HUCB-MNC cells increased CD133 expression (20 nM, 1.779 ± 0.164 vs 0.992 ± 0.216, p < 0.05; 50 nM, 2.662 ± 0.213 vs 0.992 ± 0.216, p < 0.01; 100 nM, 3.661 ± 0.351 vs 0.992 ± 0.216, p < 0.001) (Fig. 5C,E). Therefore, miR-142-3p acted on 3'UTR of CD133 mRNA to inhibit CD133 expression.
miRNA-142-3p mimic increased radiosensitivity in CD133+HUCB-MNC cells. To explore the effect of miRNA-142-3p on radiosensitivity in CD133+HUCB-MNC cells, both miRNA-142-3p mimic and miRNA-142-3p inhibitor were used to detect the effects on cell proliferation, cell apoptosis, cell cycle, AKT and ERK protein and mRNA levels after the 6 Gy radiation. MiRNA-142-3p mimic reduced CD133+HUCB-MNC cells’ proliferation rate compared with the mimic control group (10 nM, 0.580 ± 0.077 vs 0.747 ± 0.083, p < 0.05; 20 nM, 0.313 ± 0.085 vs 0.747 ± 0.083, p < 0.001; 50 nM, 0.172 ± 0.049 vs 0.747 ± 0.083, p < 0.001) (Fig. 6A), while miRNA-142-3p inhibitor increased the proliferation rate compared with the inhibitor control group (20 nM, 0.912 ± 0.038 vs 0.725 ± 0.107, p < 0.05; 50 nM, 1.126 ± 0.049 vs 0.725 ± 0.107, p < 0.01; 100 nM, 1.311 ± 0.059 vs 0.725 ± 0.107, p < 0.001) (Fig. 6B). We further explored the effect of miRNA-142-3p on cell apoptosis after 6 Gy radiation exposures. As showed in Fig. 6C,D, the proportion of apoptosis increased in the miRNA-142-3p mimic group compared with mimic control group (10 nM, 44.819% ± 3.572% vs 35.897% ± 4.880%, p < 0.01; 20 nM, 49.160% ± 8.047% vs 35.897% ± 4.880%, p < 0.01; 50 nM, 62.032% ± 9.634% vs 35.897% ± 4.880%, p < 0.001), while miRNA-142-3p inhibitor reduced the proportion of apoptosis compared with inhibitor control group (20 nM, 28.629% ± 3.572% vs 37.745% ± 3.094%, p < 0.01; 50 nM, 25.117% ± 4.496% vs 37.745% ± 3.094%, p < 0.01). The proportion of S phase cells decreased in the miRNA-142-3p mimic group compared with mimic control group at 6 Gy radiation dose (10 nM, 15.759% ± 1.096% vs 20.187% ± 1.002%, p < 0.01; 20 nM, 12.273% ± 1.030% vs 20.187% ± 1.002%, p < 0.001; 50 nM, 8.502% ± 1.382% vs 20.187% ± 1.002%, p < 0.001), and miRNA-142-3p inhibitor upregulated the proportion of S phase cells compared with inhibitor control group (20 nM, 25.967% ± 1.812% vs 21.987% ± 2.539%, p < 0.05; 50 nM, 30.757% ± 3.025% vs 21.987% ± 2.539%, p < 0.01; 100 nM, 36.595% ± 3.974% vs 21.987% ± 2.539%, p < 0.001) (Fig. 6E,F). The proportion of p-AKT/t-AKT decreased in the miRNA-142-3p mimic group compared with mimic control group at 6 Gy radiation dose (20 nM, 0.330 ± 0.046 vs 0.930 ± 0.095, p < 0.01) (Fig. 7A,B). What’s more, the proportion of p-ERK (T202/Y204)/t-ERK decreased in the miRNA-142-3p mimic group compared with mimic control group at 6 Gy radiation dose (20 nM, 0.730 ± 0.095 vs 0.967 ± 0.134, p < 0.05) (Fig. 7A,C). And the miRNA-142-3p inhibitor showed opposite effects on the p-AKT and p-ERK (T202/Y204) levels. However, no effect was observed on AKT and ERK mRNA levels (Fig. 7D,E). The results above indicated that miRNA-142-3p mimic increased radiosensitivity in CD133+HUCB-MNC cells.
Umbilical cord blood is considered as an alternative source for stem cell transplantation and therapy due to its hematopoietic and mesenchymal properties. For both HSCs and leukemia stem cells (LSCs), specific gene expression programs distinguish them from their differentiated progenies. Human HSCs are a primary target of radiation-induced leukemogenesis and provide a correlation cellular model for evaluating the risk of cancer. The CD133 is considered as a tumor marker in many cancer types. The therapeutic capacity of HUCB-MNC and stem cells is documented in animal models of focal cerebral ischemia. CD133+ HUCB-MNC reduced neuronal apoptosis in the range of normoxic controls. Radiotherapy leads to myelosuppression, but CD133 could resist radiotherapy-induced bone marrow suppression. CD133 can be phosphorylated on cytoplasmic tyrosine-828 by the Src family kinases. And the Src family kinases can be activated rapidly by multiple cell surface receptors combination and regulate many cellular processes that include proliferation, differentiation and adhesion. In our study, the results indicated that CD133+ HUCB-MNC cells were more radioresistant compared with CD133− HUCB-MNC cells due to an increase in the proliferation rate, a decrease in the radiation induced apoptosis and prolonged S phase after radiation exposure, and CD133+ HUCB-MNC cells showed higher p-AKT.

**Figure 4.** Screening of miRNAs Regulating CD133 Expression and miRNA validation by RT-PCR. (A–L) represent the expression level of hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-200c-3p, hsa-miR-4423-5p, hsa-miR-335-3p, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-22-3p, hsa-miR-30a-5p, hsa-miR-30e-5p, hsa-miR-377-3p and hsa-miR-4739 between CD133+ HUCB-MNC cells and CD133− HUCB-MNC cells at 0 and 6 Gy.

**Discussion**

Umbilical cord blood is considered as an alternative source for stem cell transplantation and therapy due to its hematopoietic and mesenchymal properties. For both HSCs and leukemia stem cells (LSCs), specific gene expression programs distinguish them from their differentiated progenies. Human HSCs are a primary target of radiation-induced leukemogenesis and provide a correlation cellular model for evaluating the risk of cancer.

The CD133 is considered as a tumor marker in many cancer types. The therapeutic capacity of HUCB-MNC and stem cells is documented in animal models of focal cerebral ischemia. CD133+ HUCB-MNC reduced neuronal apoptosis in the range of normoxic controls. Radiotherapy leads to myelosuppression, but CD133 could resist radiotherapy-induced bone marrow suppression. CD133 can be phosphorylated on cytoplasmic tyrosine-828 by the Src family kinases. And the Src family kinases can be activated rapidly by multiple cell surface receptors combination and regulate many cellular processes that include proliferation, differentiation and adhesion. In our study, the results indicated that CD133+ HUCB-MNC cells were more radioresistant compared with CD133− HUCB-MNC cells due to an increase in the proliferation rate, a decrease in the radiation induced apoptosis and prolonged S phase after radiation exposure, and CD133+ HUCB-MNC cells showed higher p-AKT.
and p-ERK levels after radiation. CD133+ is a marker of human progenitor and hematopoietic stem cells; repair signaling in CD133+ UCBC was different from CD133− UCBC and PBL. These differences included higher 53BP1 recruitment and lower endogenous DSB levels24. CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells by activating of PI3K/Akt pathway25. CD133+ cells are used for treatment of leukemia, liver regeneration, neurodegenerative diseases and myocardial infarction26.

MicroRNAs are post-transcriptional regulators which bind to complementary sequences on target messenger RNA, usually leading to translational repression or target degradation and gene silencing27. MiRNAs were proved to play important roles in control of multifaceted of HSC and LSC biology28. Recent studies have showed that roles of miRNAs in reaction to physiologic and pathologic stress such as DNA damage in fully developed tissues. For example, micro-RNA30c negatively regulates REDD1 expression in human hematopoietic and osteoblast cells after irradiation1. Our results of a luciferase assay showed that miR-142-3p silenced CD133 by binding to the 3′-UTR of CD133 mRNA, and miRNA-142-3p mimic increased radiosensitivity in CD133+ HUCB-MNC cells.

Therapeutic delivery of miR142-3p in ATRT cells suggested effective reduction in its lethality by repressing tumor growth, inhibiting invasion, enhancing radiosensitivity, and prolonging survival time in orthotopic-transplanted immunocompromised mice29. Moreover miR-142-3p directly targets CD133 to regulate its ability to confer cancer and stem cell-like features in HCC30.

Figure 5. MiR-142-3p acted on 3′UTR of CD133 mRNA to inhibit CD133 expression. (A) MiR-142-3p directly targeted the 3′ untranslated region (3′-UTR) of CD133 mRNA. (B,D) Represent the Western Blot results CD133 expression in CD133+ HUCB-MNC cells with miR-142-3p mimics. (C,E) Represent CD133 expression in CD133+ HUCB-MNC cells with miR-142-3p inhibitors.

---

and p-ERK levels after radiation. CD133+ is a marker of human progenitor and hematopoietic stem cells; repair signaling in CD133+ UCBC was different from CD133− UCBC and PBL. These differences included higher 53BP1 recruitment and lower endogenous DSB levels24. CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells by activating of PI3K/Akt pathway25. CD133+ cells are used for treatment of leukemia, liver regeneration, neurodegenerative diseases and myocardial infarction26.

MicroRNAs are post-transcriptional regulators which bind to complementary sequences on target messenger RNA, usually leading to translational repression or target degradation and gene silencing27. MiRNAs were proved to play important roles in control of multifaceted of HSC and LSC biology28. Recent studies have showed that roles of miRNAs in reaction to physiologic and pathologic stress such as DNA damage in fully developed tissues. For example, micro-RNA30c negatively regulates REDD1 expression in human hematopoietic and osteoblast cells after irradiation1. Our results of a luciferase assay showed that miR-142-3p silenced CD133 by binding to the 3′-UTR of CD133 mRNA, and miRNA-142-3p mimic increased radiosensitivity in CD133+ HUCB-MNC cells. Therapeutic delivery of miR142-3p in ATRT cells suggested effective reduction in its lethality by repressing tumor growth, inhibiting invasion, enhancing radiosensitivity, and prolonging survival time in orthotopic-transplanted immunocompromised mice29. Moreover miR-142-3p directly targets CD133 to regulate its ability to confer cancer and stem cell-like features in HCC30.

Figure 5. MiR-142-3p acted on 3′UTR of CD133 mRNA to inhibit CD133 expression. (A) MiR-142-3p directly targeted the 3′ untranslated region (3′-UTR) of CD133 mRNA. (B,D) Represent the Western Blot results CD133 expression in CD133+ HUCB-MNC cells with miR-142-3p mimics. (C,E) Represent CD133 expression in CD133+ HUCB-MNC cells with miR-142-3p inhibitors.

---
Conclusions

In conclusion, CD133+HUCB-MNC cells were more radioresistant compared with CD133−HUCB-MNC cells. CD133+HUCB-MNC cells showed higher p-AKT and p-ERK levels after radiation. The results of a luciferase assay showed that miR-142-3p silenced CD133 by binding to the 3′-UTR of CD133 mRNA. Overexpression...
of miR-142-3p in human CD133+ HUCB-MNC cells can not only inhibit the expression of CD133 but also can inhibit the proliferation in vitro, arrest cell cycle progression, and promote apoptosis. This study gains an insight into the mechanism of radiotherapy resistance and gives a new strategy for blood system disease therapies in the future. Identification of the markers under the control of miRNA-142-3p and their regulation in CD133+ HUCB-MNC cells may help develop efficient targeted treatments, improved diagnostic methods, and better prognostic evaluation.

Methods

Isolation of primary umbilical cord blood mononuclear cells. Blood samples (about 50 mL) were collected from three fresh placentas with attached umbilical cords by gravity flow. MNCs were isolated by density gradient centrifugation over Biocoll (Biochrom, Berlin, Germany) for 30 min at 400 × g and washed three times in phosphate buffered saline (PBS) (Biochrom). MNCs were counted and incubated for 30 min at 4 °C with anti-human CD133 (eBioscience, CA, USA). CD133+/− MNCs were purified by FACS (fluorescence-activated cell sorter) sorting using a FACSAria III flow cytometer (BD Biosciences, CA, USA). The FACS-sorting purity were more than 90%. The mononuclear cells were inoculated in Iscove's modified Dulbecco's medium supplied with 10% FBS, 15 ng/mL IL-3, and 5 ng/mL Granulocyte-macrophage colony-stimulating factor (GM-CSF), and cultured in a humidified 5% CO2 atmosphere at 37 °C. The medium was replaced by half at a 3-day interval until the attached cells grew to 80% confluence, and then used for the following experiments. All experimental procedures were approved by Laboratory Animal Ethics Committee of Chinese PLA general hospital. The principles
Flow Cytometry. The cells were examined for immune phenotype (CD29, CD44, CD90, CD34, CD45, CD133, and CD117). Cells were collected for cell-surface staining. The following reagents were used for surface staining: Anti-Integrin beta 1 (Alternative name: CD29) antibody [MEM-101A] (FITC) (ab21845) Anti-CD44 antibody [F10-44-2] (Phycoerythrin) (ab82529), Anti-CD90/Thy1 antibody [F15-42-1] (FITC) (ab11155), Anti-CD45 antibody [MEM-28], prediluted (Phycocyanin) (ab134202), eBioscience 11-1339-42 FITC human CD133, Anti-CD34 antibody [4H11[APG]] (FITC) (ab18227), Anti-c–Kit (Alternative name: CD117) antibody [104D2] (Phycoerythrin) (ab111245). Flow cytometry data for each of the experiments were acquired using BD FACSCalibur (BD Immunocytometry Systems). Data analysis was performed with FlowJo software (Tree Star)31.

Hematopoietic colony formation assay. A volume of $1 \times 10^5$ ml CD133+HUCB-MNC Cells or $1 \times 10^5$ ml CD133–HUCB-MNC Cells were plated in 12-well plate culture flasks coated with methylcellulose and 10 ng/ml Granulocyte colony stimulating factor (G-CSF). After 24 h, the cells were irradiated with graded doses (0, 2, 4, 6, 8 Gy) using X-ray generator (Primus High-Energy Siemens) at a dose rate of 2 Gy/min. After 10 days of incubation in a humidified 5% CO$_2$ atmosphere at 37°C, the colonies were fixed. Those colonies containing ≥50 cells were scored as viable colonies. The data were fit into the single-hit multi-target model, and the survival curve of each group was demonstrated by Graphpad prism 6.0 software (San Diego, CA, USA)32. The hematopoietic colony formation assays were performed in triplicate.

CCK8 Cell proliferation assay. CCK-8 kit (Beyotime, China) was used to detect cell viability6. Briefly, CD133+HUCB-MNC cells or CD133–HUCB-MNC cells were seeded into 96-well plate (Corning Costar, Cambridge, MA) at a density of 0.2 × 10$^4$ cells per well. After 24 h, the cells were irradiated with graded doses (0, 2, 4, 6, 8 Gy) using X-ray generator (Primus High-Energy Siemens) at a dose rate of 2 Gy/min. 14 h after radiation, 10 μL of CCK-8 solution was added, followed by incubation for 3 h at 37°C. The optical density (OD) was measured at 450 nm to reflect the cell viability. Detection was done in 6 wells per group, and blank controls were also detected. The proliferation assays were performed in triplicate.

Detection of cell apoptosis by flow cytometry. Annexin V-FITC/PI cell apoptosis detection kit (BD Biosciences, SanJose, CA) was used for the detection of apoptotic cells. Cells in logarithmic growth phase were used to prepare single cell suspension at 1 × 10$^6$ cells/ml. After addition of propidium iodide (PI) and FITC Annexin V, the apoptotic cells were detected by flow cytometry (BD Biosciences), and apoptosis rate was calculated. Experiment was done thrice, and data were analyzed with Flowjo (tree Star)33.

BrdU labeled cell cycle analysis. Briefly, cells were incubated with 10 μM BrdU for 2 h and then were fixed with 4% paraformaldehyde. After rinsed with PBS, cells were treated with 2 N HCl for 30 min. Nonspecific binding was blocked in 5% bovine serum albumin (BSA) for 1 h at room temperature. Cells were respectively incubated with mouse anti-BrdU (1:200, Millipore, MAB3222) overnight at 4°C one after another. Then followed by three times washes in PBS, they were incubated with Goat Anti-Mouse IgG H&L (Cy5)$^{	ext{TM}}$ preabsorbed (ab6563) for 1 h at room temperature. Immunofluorescence was observed using flow cytometry.

Western blot. Total proteins were extracted after treatment using a standard method and the protein concentrations were determined using Bradford method. 30 μg proteins were electrophoresed on a 12% SDS-polyacrylamide gels, followed by transferring to a nitrocellulose membrane. Membrane was incubated with the following primary antibodies: Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb (1:1000, Cat 4060), Anti-T-Akt (1:1000, Cst 9272), Anti-ERK 1/2 (1:1000, cst #9102), Anti-P-ERK 1/2 (1:2000, cst#4370) or Anti-GAPDH(H:1:1000, cst 5174), Anti-CD133 antibody - Stem Cell Marker (ab16518, 1:500). Blots were washed with TBST, then followed by the addition of the secondary antibodies goat anti-rabbit IgG HRP conjugate (1:2000, ab6721) at 37°C for 1 h. Bound antibodies were detected with enhanced chemiluminescence (ECL) reagents (Amersham, Cleveland, OH, USA) and membranes were exposed to Hyperfilm (Amersham, Cleveland, OH, USA). The intensity values of the protein were measured by ImageJ (National Institutes of Health) and normalized to that of GAPDH and expressed as a relative ratio.

RNA isolation and quantitative real-time polymerase chain reaction. After treatment, total RNA was prepared by using total RNA Kit (R6934, Omega Bio-tek Inc., GA, U.S.A.) and cDNA was synthesized from 5 μg RNA in cDNA Synthesis Kit (K1622, Fermentas International Inc., Canada) according to the manufacturer's instructions. Each PCR was performed in triplicate in a final volume of 20 μL solution: 10 μL of SYBR Green dye, 1 μL of diluted cDNA products, 0.2 μM of each paired primer, 8.6 μL deionized water. Protocols were as follows: initial denaturation for 5 min at 94°C, followed by 40 cycles denaturation for 30 s at 94°C and extension for 30 s at 58°C. The last cycle for dissociation for Erk were: Forward: 5′-CTGGGCTACACTGAGCACC-3′, Reverse: 5′-AAGTGGTCGTTGAGGGCAATG-3′. The primer sequences for Akt were: Forward: 5′-GACCACGTCCTATTTGAAG-3′, Reverse: 5′-GCCATCTATTCTTGAGGAGAATG-3′. The primer sequences for Erk were: Forward: 5′-TCACACGGGTTCTCGACAGA-3′, Reverse: 5′-ATGGACCTACAGACCAAAATATC-3′. The primer sequences for the control GAPDH were: Forward: 5′-CTGGGCTACACTGAGCACC-3′, Reverse: 5′-AAGTGGTCCTTGAGGACATG-3′. The microRNA primer sequences were shown in Supplementary table 1. Assays were performed in triplicate with the ABI7500 instrument. All data were normalized by GAPDH. Gene expression data was analyzed by the 2$^{−\Delta\Delta CT}$ method.
Screening of miRNAs Regulating CD133 Expression. An approach combining bioinformatic prediction of miRNA targets with miRNA expression profiling was used to search for putative biologically enriched functions and networks. MiRNA prediction tools included: miRanda\(^\text{1}\), RNA22\(^\text{2}\), TargetScan\(^\text{3}\), and MiRWalk\(^\text{4}\). Combined with CD133 molecular regulation and human umbilical cord blood mononuclear cell s expression, miRNA two aspects of information, the final confirmation of the following 12 miRNA\(^\text{5}\): hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-200c-3p, hsa-miR-4423-5p, hsa-miR-335-3p, hsa-miR-142-3p, hsa-miR-142-5p, hsa-miR-22-3p, hsa-miR-30a-5p, hsa-miR-30e-5p, hsa-miR-377-3p and hsa-miR-4739 (Supplementary Table 2).

miRNA validation by RT-PCR. Total RNA was reverse transcribed with miScript II RT kit (Qiagen) according to manufacturer’s instructions. qPCR was performed in triplicate on Rotor-GeneQ (Qiagen) using miScript SYBR Green PCR kit (Qiagen). Data were normalized to RNU6 microRNA expression using the Ct method. The microRNA primer sequences are illustrated in Supplementary Table 1\(^\text{1}\).

Dual luciferase reporter gene assay. The 3′UTR of CD133 (sense: 5′-GCTAGCGagggcggaa ttcttgaccg-3′, antisense: 5′-GTGGACACcagcagcatcc acccagcacc cccagcctg tg-3′) was amplified with PCR. Genomic DNA was extracted from the blood, and the 3′UTR of CD133 containing miR-142-3p binding site was amplified. The PCR products were inserted into pmirGLO vector to acquire recombinant CD133-wt. CD133\(^\text{+}\)HUCB-MNC cells were seeded into 12-well plates, and the vector (CD133-wt) was transfected into CD133\(^\text{+}\)HUCB-MNC cells using LipofectamineTM 2000 kit (Invitrogen, Carlsbad, CA, USA). 24 hours later, dual luciferase reporter gene assay kit (Promega) was used to detect the dual luciferase signals. The reagents for hsa-miR-142-3p inhibition were: hsa-miR-142-3p inhibitor (micrOFF™ hsa-miR-142-3p inhibitor, Standard, 5nmol, miR20000434-1-5) and negative control inhibitor (neg. I) (micrOFF™ inhibitor Negative Control #24, Standard, 5nmol, miR01201-1-5) by using LipofectamineTM 2000 kit (Invitrogen, Carlsbad, CA, USA). 24 hours later, dual luciferase reporter gene assay kit (Promega) was used to detect the dual luciferase signals. The reagents for hsa-miR-142-3p inhibition were: hsa-miR-142-3p inhibitor (micrOFF™ hsa-miR-142-3p inhibitor, Standard, 5nmol, miR20000434-1-5) and negative control inhibitor (neg. I) (micrOFF™ inhibitor Negative Control #24, Standard, 5nmol, miR02201-1-5).

Statistical analysis. Statistical analysis was performed with SPSS17.0 statistical software (SPSS Inc., Chicago, IL, USA). Data were expressed as mean ± SEM. One-way ANOVA in conjunction with least significant difference test was performed to determine statistical significance (P < 0.05). The difference was considered significantly if P < 0.05. * means p < 0.05, ** means p < 0.01 and *** means p < 0.001.

Data Availability. All data generated or analyzed during this study are included in this published article.

References

1. Hong, I. X., Ha, C. T., Fu, D. & Xiao, M. Micro-RNA30c Negatively Regulates REDD1 Expression in Human Hematopoietic and Osteoblast Cells after Gamma-Irradiation. Plos One 7, e48700 (2012).
2. Cardenas, C., Kwon, J. Y. & Maeng, Y. S. Human Cord Blood-Derived CD133\(^\text{+}\) progenitor cells express differentially into mesenchymal Stem Cells and Outgrowth Endothelial Cells. Stem Cells International, 2016, (2016-12-18) 2016 (2016).
3. Kiernan, J. et al. Clinical Studies of Ex Vivo Expansion to Accelerate Engraftment After Umbilical Cord Blood Transplantation: A Systematic Review. Transfusion Medicine Reviews 31 (2016).
4. Sah, S. K. et al. Effects of Human Mesenchymal Stem Cells Coculture on Calcium-Induced Differentiation of Normal Human Keratinocytes. Stem Cells 35 (2017).
5. Yong, K. S. M. et al. Human CD34\(^\text{+}\)CD33\(^\text{lo}\) fetal liver cells support the expansion of human CD34\(^\text{+}\)CD133\(^\text{hi}\) hematopoietic stem cells. Cellular & Molecular Immunology 13, 605–614 (2016).
6. Li, W., Lee, M. R., Choi, E. & Cho, M. Y. Clinicopathological Significance of Survivin Expression in Relation to CD133 Expression in Surgically Resected Stage II or III Colorectal Cancer. Journal of Pathology & Translational Medicine 51, 17–23 (2016).
7. Jang, J. W. et al. CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma. Cancer Letters 389, 1–10 (2017).
8. Takahashi, M. et al. CD133 is a positive marker for a distinct class of primitive human cord blood-derived CD34-negative hematopoietic stem cells. Leukemia 28, 1308–1315 (2014).
9. Sakai, Y. et al. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: A potential predictor of progressive clinical courses. Human Pathology (2016).
10. Golden, J. E. et al. Human Umbilical Cord Blood Cells Alter Blood and Spleen Cell Populations After Stroke. Translational Stroke Research 3, 491 (2012).
11. Cattaneo, M. et al. A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes. Journal of Cellular Physiology 230, 1770 (2015).
12. Liao, Q., Wang, B., Li, X. & Jiang, G. miRNAs in acute myeloid leukemia. Oncotarget 8, 3666 (2017).
13. Chen, X., Xiong, W. & Li, H. Comparison of microRNA expression profiles in KS62-cells-derived microvesicles and parental cells, and analysis of their roles in leukemia. Oncology Letters 12, 4937–4948 (2016).
14. Gangaraju, V. K. & Lin, H. MicroRNAs: key regulators of stem cells. Nature Reviews Molecular Cell Biology 10, 116–125 (2009).
15. Choi, J. et al. MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis. Blood 128, 2117 (2016).
16. Chang, C. et al. MicroRNA-134-3p is a novel potential inhibitor of human ovarian cancer stem cells by targeting RAB27A. Gene 605, 99–107 (2017).
17. Shen, W. W., Zeng, Z., Zhu, W. X. & Fu, G. H. MiR-142-3p functions as a tumor suppressor by targeting CD133, ABCG2, and Lgr5 in colon cancer cells. Journal of Molecular Medicine 91, 989–1000 (2013).
18. Reich, D. M. et al. Neuronal hypoxia in vitro: Investigation of therapeutic principles of HUCB-MNC and CD133+ stem cells. Bmc Neurosciences 9, 1–12 (2008).
19. Meng, X. et al. Comparative analysis of microRNA expression in human mesenchymal stem cells from umbilical cord and cord blood. Genomics 107, 124–131 (2016).
20. Girdlestone, J. Mesenchymal stromal cells with enhanced therapeutic properties. Stem Cells Translational Medicine 3, 1405–1416 (2016).
21. Coir, I. et al. Hematopoietic stem and progenitor cell migration after hypofractionated radiation therapy in a murine model. Int J Radiat Oncol Biol Phys 87, 1162–1170 (2013).
22. Boivin, D. et al. The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases. Biochemistry 48, 3998 (2009).
23. Chai, S. et al. Regulatory role of miR-142-3p on the functional hepatic cancer stem cell marker CD133. Oncotarget 5, 5725–5735 (2014).
24. Vasilyev, S. A., Kubes, M., Markova, E. & Belyaev, I. DNA damage response in CD133+stem/progenitor cells from umbilical cord blood: low level of endogenous foci and high recruitment of 53BP1. International Journal of Radiation Biology 89, 301–309 (2013).
25. Wei, Y. et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proceedings of the National Academy of Sciences of the United States of America 110, 6829–6834 (2013).
26. Bissels, U. et al. Combined Characterization of microRNA and mRNA Profiles Delineates Early Differentiation Pathways of CD133+ and CD34+ Hematopoietic Stem and Progenitor Cells. Stem Cells 29, 847–857 (2011).
27. Djuranovic, S., Nahvi, A. & Green, R. A parsimonious model for gene regulation by miRNAs. Science 331, 550–553 (2011).
28. Roden, C. & Lu, J. MicroRNAs in Control of Stem Cells in Normal and Malignant Hematopoiesis. Current Stem Cell Reports 2, 183–196 (2016).
29. Lee, Y. Y. et al. MicroRNA142-3p promotes tumor-initiating and radioresistant properties in malignant pediatric brain tumors. Cell Transplantation 23, 669 (2014).
30. Souza, C. F. D., Napoli, P. D., Han, S. W. & Lima, V. C. D. Mesenchymal stem cells: are they appropriate for cardiac regeneration? Rev. bras.cardiol.invasiva 18, 344–353 (2010).
31. Lustberg, M. B. et al. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 16, R23 (2014).
32. Tsuyoshi, Y., Toshitaka, Y., Hiroaki, Y., Atsushi, O. & Shinichi, S. Dexamethasone Regulates EphA5, a Potential Inhibitory Factor with Osteogenic Capability of Human Bone Marrow Stromal Cells. Stem Cells Int 2016, 1301608 (2016).
33. Liu, Z., Yao, L., Tan, B., Li, L. & Chen, B. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism. Oncology Letters 12, 5349 (2016).
34. Betel, D., Koppal, A., Agius, P., Sander, C. & Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biology 11, R90 (2010).
35. Loher, P. & Rigoutsos, I. Interactive Exploration of RNA22 MicroRNA Target Predictions. Bioinformatics 28, 3322–3323 (2012).
36. Chiang, H. R. et al. Mammalian microRNAs: experimental evaluation of novel and previously annotated genes. Genes & Development 24, 992 (2010).
37. Dweep, H., Gretz, N. & Sticht, C. miRWalk database for miRNA-target interactions. Methods in Molecular Biology 1182, 289 (2014).

Acknowledgements
This work was supported by grants from the Military Medical Science Youth Training Project (no. 14QNP107), the National Key R&D Program of China, Stem Cell and Translation Research (no. 2017YFA0106200), the National Natural Science Foundation of China (no. 81402319), the Beijing Nova Program (no. Z161100004916133).

Author Contributions
F.Y., L.L., Y.H.L. and Y.H. designed experiments. F.Y. and L.L. performed experiments. F.Y., L.L., Y.H.L. and Y.H. wrote the manuscript. Y.H. contributed to data analysis and discussed the results. All authors read and approved the final manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23968-1.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018